BACE1 and Alzheimer disease: Paudel and colleagues additionally evaluated the bromophenol (54) as a mixed-type inhibitor of AChE, a competitive inhibitor of butyrylcholinesterase (BChE), as well as noncompetitive inhibition of BACE1 in vitro, indicating therapeutic potential for AD management [144].